Carzenide
Based on 1 Customer Validation
Carzenide (4-Sulfamoylbenzoic acid) is the major circulating metabolite of Mafenide (HY-B0614) in plasma. Carzenide is a strong CAII competitive inhibitor. Carzenide can be used in the research of epilepsy and cervical cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.45%
- CAS No.: 138-41-0
- Formule: C7H7NO4S
- Masse moléculaire:201.20
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Drug Repurposing Compound Library
HY-L035
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Drug Metabolite Library
HY-L098
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Off-patent Drug Library
HY-L141
-
Metabolic Enzyme Compound Library
HY-L146
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Drug Fragment Library
HY-L904
Activité biologique
|
CA Ⅱ |
Carzenide (100 μM; 2 h; pretreatment) renders the fluorescence signal induced by FMRs-CA negligible in HeLa cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 138-41-0
-
Appearance Solid
-
Masse moléculaire 201.20
-
Formule C7H7NO4S
-
Color White to off-white
-
SMILES
O=C(O)C1=CC=C(S(=O)(N)=O)C=C1
-
Synonyms
4-Sulfamoylbenzoic acid
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Solvant et solubilité
DMSO : 100 mg/mL (497.02 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (12.43 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (273 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Weisdorf DJ, et al. Mafenide (Sulfamylon) inhibits plasmin fibrinolytic activity. Thromb Haemost. 1988 Jun 16;59(3):440-4. PMID: 2973151. [Content Brief]
[2]. Zhang F, et al. Imaging of Carbonic Anhydrase Level in Epilepsy with an Environment-Sensitive Fluorescent Probe. Anal Chem. 2023 Oct 10;95(40):14833-14841. [Content Brief]
[3]. Abo-Ashour MF, et al. Novel synthesized SLC-0111 thiazole and thiadiazole analogues: Determination of their carbonic anhydrase inhibitory activity and molecular modeling studies. Bioorg Chem. 2019 Jun;87:794-802. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.9702 mL | 24.8509 mL | 49.7018 mL | 124.2545 mL |
| 5 mM | 0.9940 mL | 4.9702 mL | 9.9404 mL | 24.8509 mL | |
| 10 mM | 0.4970 mL | 2.4851 mL | 4.9702 mL | 12.4254 mL | |
| 15 mM | 0.3313 mL | 1.6567 mL | 3.3135 mL | 8.2836 mL | |
| 20 mM | 0.2485 mL | 1.2425 mL | 2.4851 mL | 6.2127 mL | |
| 25 mM | 0.1988 mL | 0.9940 mL | 1.9881 mL | 4.9702 mL | |
| 30 mM | 0.1657 mL | 0.8284 mL | 1.6567 mL | 4.1418 mL | |
| 40 mM | 0.1243 mL | 0.6213 mL | 1.2425 mL | 3.1064 mL | |
| 50 mM | 0.0994 mL | 0.4970 mL | 0.9940 mL | 2.4851 mL | |
| 60 mM | 0.0828 mL | 0.4142 mL | 0.8284 mL | 2.0709 mL | |
| 80 mM | 0.0621 mL | 0.3106 mL | 0.6213 mL | 1.5532 mL | |
| 100 mM | 0.0497 mL | 0.2485 mL | 0.4970 mL | 1.2425 mL |
Carzenide Related Classifications
HY-B0989 Related Classifications
Powered by Bioz